Information Consultation by Radiotherapy Manipulator

Cancer Clinical Trial

— INFORTH  

Official title:

Information Consultation by a Manipulator Radiotherapy: Impact on Information to Patients Treated With Radiotherapy for Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02867462
• Other study ID #: 2012/63 INFORTH
• Status: Completed
• Phase: N/A
• First received: August 11, 2016
• Last updated: November 30, 2017
• Start date: April 2013
• Est. completion date: May 10, 2017

Study information

• Verified date: August 2016
• Source: Centre Antoine Lacassagne
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The medical teams are increasingly sought by patients to get the most possible information, probably expressed in a different form and thereby supplementing the information already received. Coulter et al. reached similar conclusions in their study of the writings of patient information documents. They point out, moreover, the best adaptation of the patients better informed compared to those with less or no information.

This need for information varies over time. It is present before treatment begins, continues during treatment and persists after treatment. Given the specific features of radiotherapy, the manipulators are important interlocutors to participate in the accompanying caregiver time.

In conclusion, the quality of information delivered to the patient has been poorly evaluated, let alone with validated tools in this area.

The impact of information on the tolerance of the treatment also needs to be confirmed, knowing that an informed patient seems less anxious and better prepared for future treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 308
• Est. completion date: May 10, 2017
• Est. primary completion date: May 10, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with cancer of the head and neck, esophagus, stomach, breast, rectum, anal canal, prostate, lung, bile duct, pancreas or female genital histologically proven

• Patient being treated by radiotherapy alone or combined with chemotherapy / immunotherapy, exclusive treatment or adjuvant

• Age over 18 years

Exclusion Criteria:

• Patient has been treated with radiation to the tumor site

• Patient with metastatic stage disease

• Patient targeted for hypofractionated radiotherapy

Related Conditions & MeSH terms

• Cancer

Intervention

Other:
• Standard care
standard care
• manipulator consultation radiotherapy added to standard care

Locations

Country	Name	City	State
France	Centre Antoine LACASSAGNE	Nice

Sponsors (1)

Lead Sponsor	Collaborator
Centre Antoine Lacassagne

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	EORTC QLQ-INFO25	amount of information received by patients in the case of a standard support and if the patient has a consultation with a radiation therapy manipulator, assessed using the questionnaire EORTC QLQ-INFO25 before the first radiotherapy session	12 weeks